Citius Pharmaceuticals, Inc. develops innovative therapeutics for patients with critical diseases. The company focuses on advancing medical treatments for conditions such as infectious diseases and oncology. The company self-described as unlocking potential faster.

Citius Pharmaceuticals, Inc.

No relevant search results found: There were no relevant search results returned for the query related to Citius Pharmaceuticals, Inc. This suggests that there is currently no data available on Northdata for the company, indicating the lack of public records or information that could match the provided company base data.

Domain Not Resolving

Euro

HSTS

DNSSEC

Content Delivery Network

Global Site Tag

reCAPTCHA v2

ASP.NET Ajax

SMTP2GO

Google Analytics IP Anonymization

Myron Holubiak

William Kane

Issam Raad

Suren Dutia

Carol Webb

Mark Rupp

Howard Safir

Eugene Holuka

Jaime Bartushak

Gary Talarico

Executive Vice President of Operations

Chief Executive Officer

Leonard Mazur

CEO & Chairman of the Board of Directors

John Westman

Vice President Project Management

Kelly Creighton

EVP of Chemistry, Manufacturing & Controls (CMC)

Alan Lader

Vice President of Clinical Operations

Andrew Scott

Vice President of Corporate Development

Greater New York Area Therapeutics Companies

East Coast Companies that Exited (Top 10K)

East Coast Public Companies With More Than 10 Employees

Medical Companies that Exited

Citius Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapeutic products for large and growing markets. 

Citius products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve market position or market exclusivity. By using previously approved drugs with substantial safety and efficacy data, Citius seeks to reduce the risks associated with pharmaceutical product development.

Citius is advancing two proprietary product candidates, our Mino-Lok™ product and a Hydrocortisone-Lidocaine formulation. Citius believes the markets for its products are large and underserved by the current standard of care.

Post-IPO Equity - Citius Pharmaceuticals

NJEDA

Grant - Citius Pharmaceuticals

Post-IPO Debt - Citius Pharmaceuticals

Cranford

New Jersey

United States

North America

Citius Pharmaceuticals

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Citius Pharmaceuticals (CTXR) Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok Program and Pathway to Approval

Citius Pharmaceuticals trading halted, news pending

Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split

Citius Pharmaceuticals announces 1-for-25 reverse stock split

Citius Pharmaceuticals just downgraded at D. Boral Capital, here's why

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

Citius Pharmaceuticals announces $3M registered direct offering

A recombinant engineered fusion protein combining interleukin-2 and diphtheria toxin, targeting malignant T-cells and regulatory T-cells in cancer treatment.

An antibiotic lock solution used to treat catheter-related bloodstream infections by salvaging the central venous catheters.

India

Asia

Philippines

Argentina

South America

Japan

HTML5

Microsoft Outlook

Google Analytics

F5 NGINX

Modernizr

Adobe Flash

Office 365

DigiCert

Vimeo

Disqus

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Dec 4, 2024 8:45 PM	86a85ee4
public peers	general	Nov 7, 2024 5:09 AM	febaf632
news daily refresh	general	Dec 23, 2024 12:00 AM	56dd043b
news processing daily refresh	general	Dec 20, 2024 4:34 PM	26967a37
news impact assignment daily	general	Dec 20, 2024 6:28 AM	8177fff2
news processing basic	general	Dec 4, 2024 2:28 PM	b2346f7c
company summary	general	Dec 20, 2024 6:37 AM	4fd2b6c6
signals	general	Dec 4, 2024 11:57 AM	0c47eaa8
crunchbase trigger	general	Dec 4, 2024 11:57 AM	cd280d5d
crunchbase profile	general	Dec 4, 2024 12:46 PM	5d4cc4c9
li profile	general	Nov 7, 2024 5:09 AM	d38fc8aa
translate crunchbase fundingrounds	general	Dec 4, 2024 1:36 PM	7d97fb6c
peers	general	Dec 4, 2024 11:57 AM	34714b82
news basic	general	Dec 4, 2024 11:57 AM	dab4b0ef
bundesanzeiger	filings
financials download nd	financials	Dec 4, 2024 12:43 PM	e199738a
private financials	financials

COM:CITIUSPHARMA

Citius Pharmaceuticals, Inc.

Last Close

0.17

22/11 21:00

Market Cap

134.75M

Beta: -

Volume Today

15.99M

Avg: -